268 related articles for article (PubMed ID: 24175853)
1. The blood neutrophil-to-lymphocyte ratio predicts survival in patients with advanced hepatocellular carcinoma receiving sorafenib.
Zheng YB; Zhao W; Liu B; Lu LG; He X; Huang JW; Li Y; Hu BS
Asian Pac J Cancer Prev; 2013; 14(9):5527-31. PubMed ID: 24175853
[TBL] [Abstract][Full Text] [Related]
2. Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
da Fonseca LG; Barroso-Sousa R; Bento Ada S; Blanco BP; Valente GL; Pfiffer TE; Hoff PM; Sabbaga J
Med Oncol; 2014 Nov; 31(11):264. PubMed ID: 25273866
[TBL] [Abstract][Full Text] [Related]
3. Adjuvant sorafenib therapy in patients with resected hepatocellular carcinoma: evaluation of predictive factors.
Zhang W; Zhao G; Wei K; Zhang Q; Ma W; Wu Q; Zhang T; Kong D; Li Q; Song T
Med Oncol; 2015 Apr; 32(4):107. PubMed ID: 25750040
[TBL] [Abstract][Full Text] [Related]
4. Neutrophil-lymphocyte ratio as a predictor of outcomes for patients with hepatocellular carcinoma undergoing TAE combined with Sorafenib.
Wei K; Wang M; Zhang W; Mu H; Song TQ
Med Oncol; 2014 Jun; 31(6):969. PubMed ID: 24793745
[TBL] [Abstract][Full Text] [Related]
5. Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies.
Bruix J; Cheng AL; Meinhardt G; Nakajima K; De Sanctis Y; Llovet J
J Hepatol; 2017 Nov; 67(5):999-1008. PubMed ID: 28687477
[TBL] [Abstract][Full Text] [Related]
6. Changes in the neutrophil-to-lymphocyte ratio predict the prognosis of patients with advanced hepatocellular carcinoma treated with sorafenib.
Hong YM; Yoon KT; Hwang TH; Heo J; Woo HY; Cho M
Eur J Gastroenterol Hepatol; 2019 Oct; 31(10):1250-1255. PubMed ID: 30925530
[TBL] [Abstract][Full Text] [Related]
7. Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.
Casadei Gardini A; Scarpi E; Faloppi L; Scartozzi M; Silvestris N; Santini D; de Stefano G; Marisi G; Negri FV; Foschi FG; Valgiusti M; Ercolani G; Frassineti GL
Oncotarget; 2016 Oct; 7(41):67142-67149. PubMed ID: 27613839
[TBL] [Abstract][Full Text] [Related]
8. Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.
Howell J; Pinato DJ; Ramaswami R; Arizumi T; Ferrari C; Gibbin A; Burlone ME; Guaschino G; Toniutto P; Black J; Sellers L; Kudo M; Pirisi M; Sharma R
Oncotarget; 2017 May; 8(22):36161-36170. PubMed ID: 28212535
[TBL] [Abstract][Full Text] [Related]
9. Predictive role of the neutrophil-to-lymphocyte ratio in patients with advanced hepatocellular carcinoma receiving sorafenib.
Tanoglu A; Karagoz E
Asian Pac J Cancer Prev; 2014; 15(2):1063. PubMed ID: 24568452
[No Abstract] [Full Text] [Related]
10. Survival and cost-effectiveness of sorafenib therapy in advanced hepatocellular carcinoma: An analysis of the SEER-Medicare database.
Parikh ND; Marshall VD; Singal AG; Nathan H; Lok AS; Balkrishnan R; Shahinian V
Hepatology; 2017 Jan; 65(1):122-133. PubMed ID: 27770556
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib for the treatment of advanced hepatocellular carcinoma with extrahepatic metastasis: a prospective multicenter cohort study.
Nakano M; Tanaka M; Kuromatsu R; Nagamatsu H; Tajiri N; Satani M; Niizeki T; Aino H; Okamura S; Iwamoto H; Shimose S; Shirono T; Koga H; Torimura T;
Cancer Med; 2015 Dec; 4(12):1836-43. PubMed ID: 26471348
[TBL] [Abstract][Full Text] [Related]
12. Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma: a prospective cohort study.
Kim HY; Lee DH; Lee JH; Cho YY; Cho EJ; Yu SJ; Kim YJ; Yoon JH
BMC Cancer; 2018 Mar; 18(1):307. PubMed ID: 29558905
[TBL] [Abstract][Full Text] [Related]
13. Identification of clinical biomarkers for patients with advanced hepatocellular carcinoma receiving sorafenib.
Lamarca A; Abdel-Rahman O; Salu I; McNamara MG; Valle JW; Hubner RA
Clin Transl Oncol; 2017 Mar; 19(3):364-372. PubMed ID: 27541594
[TBL] [Abstract][Full Text] [Related]
14. [Plasma Biomarkers as Predictive Factors for Advanced Hepatocellular Carcinoma with Sorafenib].
Shiozawa K; Watanabe M; Ikehara T; Matsukiyo Y; Kogame M; Shinohara M; Kikuchi Y; Igarashi Y; Sumino Y
Gan To Kagaku Ryoho; 2016 Jul; 43(7):863-7. PubMed ID: 27431630
[TBL] [Abstract][Full Text] [Related]
15. Duration of stable disease is associated with overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.
Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
Dig Dis; 2014; 32(6):705-10. PubMed ID: 25376287
[TBL] [Abstract][Full Text] [Related]
16. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.
Chen D; Zhao P; Li SQ; Xiao WK; Yin XY; Peng BG; Liang LJ
Eur J Surg Oncol; 2013 Sep; 39(9):974-80. PubMed ID: 23845703
[TBL] [Abstract][Full Text] [Related]
18. Determinants of survival after sorafenib failure in patients with BCLC-C hepatocellular carcinoma in real-world practice.
Lee IC; Chen YT; Chao Y; Huo TI; Li CP; Su CW; Lin HC; Lee FY; Huang YH
Medicine (Baltimore); 2015 Apr; 94(14):e688. PubMed ID: 25860213
[TBL] [Abstract][Full Text] [Related]
19. The effect of locoregional therapies in patients with advanced hepatocellular carcinoma treated with sorafenib.
Sarpel U; Spivack JH; Berger Y; Heskel M; Aycart SN; Sweeney R; Edwards MP; Labow DM; Kim E
HPB (Oxford); 2016 May; 18(5):411-8. PubMed ID: 27154804
[TBL] [Abstract][Full Text] [Related]
20. Decreased blood flow after sorafenib administration is an imaging biomarker to predict overall survival in patients with advanced hepatocellular carcinoma.
Arizumi T; Ueshima K; Chishina H; Kono M; Takita M; Kitai S; Inoue T; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
Dig Dis; 2014; 32(6):733-9. PubMed ID: 25376291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
